Monoclonal antibodies binding to different epitopes of CD20 differentially sensitizes DLBCL to different classes of chemotherapy
To investigate the differential gene expression profiles induced by rituximab and ofatumumab, we treated DLBCL cell lines U2932 and TMD8 with these monoclonal antibodies and analyzed their gene expression profiles Overall design: Comparative gene expression profiling analysis of RNA-seq data for U2932 and TMD8 treated with rituximab or ofatumumab